Nicolaus Radford, who founded Nauticus Robotics and took it all the way to IPO, shares details of his new company, PersonaAI. Image via LinkedIn

For his next act, Houston entrepreneur Nicolaus Radford has started — in what he describes as an "anti-stealth" capacity — a new company that hopes to bring humanoid robotics out of science fiction novels and into manufacturing floors.

Radford, who saw his last company, Nauticus Robotics, from founding to IPO, left the company in January. He tells InnovationMap that he started receiving some compelling offers at other robotics companies, but none of them felt like a fit. However, he just couldn't get the idea of advancing humanoid robotics out of his head.

"Humanoids are the holy grail of all of robotics," Radford says. "It's what every science fiction writer's always dreamed about.

"It is the future," he continues. "And now with this generative AI moment of 2022 where these machines look a lot more capable, flexible, reprogrammable — they can reason in real time. That's a huge deal."

Radford says he got a call from his friend, Jerry Pratt, who was the CTO at humanoid robotics company Figure AI. Pratt and Radford both worked in robotics at NASA and each have decades of experience in the tech world. The conversation really sealed the deal for Radford, and the two officially launched Persona AI in a LinkedIn post that Radford says shocked him with how much interest the community had.

Radford says that with all this interest, he wants to open up the company to more co-founders than just himself and Pratt, who's based in Florida.

"We're going to give a significant amount of the company out to the early joiners, more so than is probably typical," Radford says. "And it's because we know it takes a village, and we want to highlight that to everybody."

"We're trying to crowdsource the company," he continues. "We've coined that we're anti stealth."

Specifically, Radford says he's looking at growing the team to about 25 people in the next year, alongside raising early funding. He's looking for people with a diverse tech background with well-rounded experience.

"Robotics and humanoids in particular are just so multidisciplinary," Radford says. "Humanoids are a hundred-thousand-piece puzzle, and you're trying to put this puzzle together."

And for Radford, assembling that puzzle in Houston is of utmost importance. The company is headquartered here, and Radford is currently working with The Ion to set up an office there.

"We're exceptionally excited to put (the company) in Houston," he says. "It would be incredible for the city — there's a lot of industrial manufacturing here and a lot of warehousing. ... I still have this desire to shine a light on Houston's tech scene because I believe it is unsung, underappreciated, and quite capable."

The potential for this technology is huge — Radford estimates it as a $3 trillion market — but the first industry he plans on tackling is automotive, but he also sees promise in the medical, energy, and home industries.

"We think automotive is going to be a first-mover market. There's a lot of publicly announced partnerships between advanced robotics companies and humanoid companies and automotive," he says. "These folks are showing a willingness to put something out in the press that says they're developing a humanoid or piloting a humanoid. That's huge.

With this expressed interest, technology advancement, and large labor shortage, Radford is convinced now is the time for humanoid robotics — and for Persona AI.

"We're at a technology tipping point where it makes sense that these machines can do this, and there's an investment community willing to finance it," Radford says. "I think the first time in all of robotic history we're closer than we've ever been to making this a reality."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."